AMRI Completes Strategic European Acquisition
Complete the form below to unlock access to ALL audio articles.
Albany Molecular Research, Inc. has announced that it has completed the acquisition of ComGenex, located in Budapest, Hungary.
On January 30, AMRI announced the signing of a stock purchase agreement to acquire ComGenex. The completed acquisition provides AMRI with an immediate presence in Europe.
In combination with AMRI's facilities in the U.S. and Asia, the acquisition enhances the company's ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.
"All of us at AMRI welcome ComGenex employees to our team. We look forward to achieving the synergies that can occur when two strong organizations combine resources," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D.